XML 16 R6.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statement of Changes in Stockholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Series 10 Convertible Preferred Stock
Redemption Value
Series 9 Preferred Stock
Redemption Value
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Total Parent Equity
Non- Controlling Class B Units
Total
Balance at Dec. 31, 2024   $ 1,331 $ 2 $ 99,425 $ (622) $ (93,562)     $ 6,574
Balance (in Shares) at Dec. 31, 2024   1,331 1,685,021            
Common shares issued for net cash proceeds of ATM offering   1,667     1,667
Common shares issued for net cash proceeds of ATM offering (in Shares)   169,299            
Common shares issued for net cash proceeds of public offerings   $ 0 $ 2 17,900     17,902
Common shares issued for net cash proceeds of public offerings (in Shares)   2,219,746            
Common shares issued for conversion of debt   750     750
Common shares issued for conversion of debt (in Shares)   240,229            
Common shares issued for exercise of liability classified warrants   408     408
Common shares issued for exercise of liability classified warrants (in Shares)   300,000            
Redemption of Series 9 preferred stock   $ (1,331) (96)     (1,427)
Redemption of Series 9 preferred stock (in Shares)   (1,331)            
Stock-based compensation   455     455
Stock-based compensation (in Shares)              
Cumulative translation adjustment   467     467
Rounding adjustment for fractional shares resulting from 1-for-250 reverse stock split     $ 1 4     5
Rounding adjustment for fractional shares resulting from 1-for-250 reverse stock split (in Shares)   173,245            
Net loss attributable to parent   (12,872)     (12,872)
Net income attributable to noncontrolling interest                
Balance at Mar. 31, 2025   $ 5 120,513 (155) (106,434)     13,929
Balance (in Shares) at Mar. 31, 2025   4,787,540            
Balance at Dec. 31, 2025 $ 21,793   $ 33 157,354 881 (162,323) $ 17,738 $ 10,005 27,743
Balance (in Shares) at Dec. 31, 2025 25,000   32,786,816            
Common shares issued in exchange of Series 9 Preferred Stock $ (21,793)   $ 1 (1,945) (23,737) (23,737)
Common shares issued in exchange of Series 9 Preferred Stock (in Shares) (25,000)   1,721,980            
Stock-based compensation   4,847 4,847 4,847
Stock-based compensation (in Shares)              
Common shares issued for exercise of liability classified warrants   $ 4 10,734 10,738 10,738
Common shares issued for exercise of liability classified warrants (in Shares)   3,963,408            
Series 9 Preferred Stock dividend accrual   (42) (42) (42)
Disposition of the Inpixon Business (Note 16)   (881) (881) (881)
Net loss attributable to parent   (35,270) (35,270) (35,270)
Net income attributable to noncontrolling interest   272 272
Balance at Mar. 31, 2026   $ 38 $ 170,948 $ (197,593) $ (26,607) $ 10,277 $ (16,330)
Balance (in Shares) at Mar. 31, 2026   38,472,204